Claims for Patent: 6,384,049

Summary for Patent: 6,384,049

Title:	Cancer treatment
Abstract:	This invention is a method of treating cancer, including carcinomas and sarcomas through the administration of a pharmaceutical composition containing a pyridinylimidazole carbamate. The pyridinylimidazole carbamate is selected from the group consisting of: ##STR1## wherein X is independently selected from the group consisting of halo, for example, bromo, fluoro, chloro, iodo; hydroxyl, alkyl of less than 8 carbon atoms or alkoxy of less than 8 carbon atoms; n is a positive integer less than 4; R is hydrogen or an alkyl group of from 1 to 8 carbons and its pharmaceutically acceptable salts and prodrugs thereof.
Inventor(s):	Camden; James Berger (West Chester, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	09/578,281
Patent Claims:	1. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising a pyridinylimidazole carbamate of the formula: ##STR7## wherein X is independently selected from the group consisting of hydrogen halo, hydroxyl, alkyl of less than 8 carbon atoms and alkoxy of less than 8 carbon atoms; n is a positive integer less than 4; and R and R.sub.1 are independently selected from hydrogen, or an alkyl group of from 1 to 8 carbons, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. 2. A method according to claim 1 wherein said cancer is prostate cancer. 3. A method according to claim 1 wherein said cancer is breast cancer. 4. A method according to claim 1 wherein said cancer is colon cancer. 5. A method according to claim 1 wherein said cancer is lung cancer. 6. A method according to claim 1 wherein said cancer is pancreatic cancer. 7. A method according to claim 1 wherein said cancer is ovarian cancer. 8. A method according to claim 1 wherein said cancer is a sarcoma. 9. A method according to claim 1 wherein said cancer is a lymphoma. 10. A method according to claim 1 wherein said pyridinylimidazole carbamate is ##STR8## or a pharmaceutically acceptable acid salt or a prodrug thereof. 11. A method according to claim 10 wherein said pharmaceutically acceptable salt is a hydrochloride salt. 12. A method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of a combination therapy comprising (1) a pyridinylimidazole carbamate of the formula: ##STR9## wherein X is selected from the group consisting of hydrogen, bromo, fluoro, chloro, iodo, alkyl of less than 7 carbon atoms and alkoxy of less than 7 carbon atoms; n is a positive integer less than 4; R is hydrogen or an alkyl group of from 1 to 8 carbon atoms; and R.sub.1 is aliphatic hydrocarbon of less than 7 carbon atoms or a pharmaceutically acceptable salt or prodrug thereof and (2) a safe and effective amount of another chemotherapeutic agent. 13. A method according to claim 12 wherein said cancer is prostate cancer. 14. A method according to claim 12 wherein said cancer is ovarian cancer. 15. A method according to claim 12 wherein said cancer is pancreatic cancer. 16. A method according to claim 12 wherein said cancer is breast cancer. 17. A method according to claim 12 wherein said cancer is lung cancer. 18. A method according to claim 12 wherein said cancer is colon cancer. 19. A method according to claim 12 wherein said pyridinylimidazole carbamate has the formula: ##STR10## wherein X is hydrogen; n is a positive integer less than 4; and R and R.sub.1 are hydrogen or an alkyl group of from 1 to 4 carbons. 20. A method according to claim 19 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, alkylating agent, antimetabolite, tubulin-interactive agent, hormonal agent, Asparaginase and hydroxyurea. 21. A method according to claim 19 wherein said chemotherapeutic agent is selected from the group consisting of Asparaginase, hydroxyurea, Cisplatin, Cyclophosphamide, Altretamine, Bleomycin, Dactinomycin, Doxorubicin, Etoposide, Teniposide, paclitaxel, cytoxan, 2-methoxycarbonylaminobenzimidazole carbamate and Plicamycin. 22. A method according to claim 19 wherein said chemotherapeutic agent is selected from the group consisting of Methotrexate, Fluorouracil, Fluorodeoxyuridine, CB3717, Azacitidine, Floxuridine, Mercaptopurine, 6-Thioguanine, Pentostatin, Cytarabine, and Fludarabine. 23. A method according to claim 19 further comprising a safe and effective amount of a potentiator. 24. A method according to claim 23, wherein said potentiator is selected from the group consisting of procodazole, triprolidine, propionic acid, monensin, an anti-sense inhibitor of the RAD51 gene, bromodeoxyuridine, dipyridamole, indomethacin, a monoclonal antibody, an anti-transferrin receptor immunotoxin, metoclopramide, 7-thia-8-oxoguanosine, N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine, N-[4-[(4-fluorphenyl)sulfonly]phenyl] acetamide, leucovorin, heparin, heparin sulfate, cimetidine, a radiosensitizer, a chemosensitizer, a hypoxic cell cytotoxic agent, muramyl dipeptide, vitamin A, 2'-deoxycoformycin, a bis-diketopiperazine derivative, and dimethyl sulfoxide.

Details for Patent 6,384,049

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2039-02-26